Antiretroviral therapy (ART) stops HIV from copying itself inside your body. It does this by blocking the virus at specific stages of its life cycle, using a combination of drugs that each target a different step. The result: the amount of virus in your blood drops to undetectable levels, your immune system recovers, you stay healthy, and you can’t pass HIV to sexual partners. The World Health Organization recommends starting ART as soon as possible after diagnosis, regardless of symptoms or immune cell counts.
How ART Blocks the Virus
HIV has a multi-step process for hijacking your immune cells. It attaches to a type of white blood cell called a CD4 cell, fuses with it, converts its own genetic material into a form the cell can read, inserts that material into the cell’s DNA, and then uses the cell’s machinery to produce new copies of itself. Each new virus buds off the cell surface and goes on to infect more CD4 cells.
ART uses drugs from different classes, each designed to jam a specific step in that sequence. Some prevent the virus from entering the cell in the first place by blocking the surface proteins it latches onto. Others stop the virus from converting its RNA into DNA, a critical early step in replication. A widely used class called integrase inhibitors prevents viral DNA from being stitched into the cell’s own DNA. And protease inhibitors interfere with the final assembly of new virus particles, leaving them unable to infect other cells.
A standard ART regimen combines drugs from at least two of these classes. The reason for using multiple drugs together is simple: if the virus mutates in a way that escapes one drug, the other drugs still block it. This combination approach is what makes modern ART so effective at driving the virus down to undetectable levels.
What Happens to the Virus After You Start
Once you begin ART, the amount of HIV in your blood (your viral load) starts to fall. For most people, it takes roughly 6 to 8 months to reach what’s considered “undetectable,” meaning standard lab tests can no longer find the virus in a blood sample. The median time in clinical studies is about 7.7 months, though some people get there faster depending on how high their viral load was at the start and how consistently they take their medication.
Undetectable does not mean the virus is gone. HIV inserts its genetic material into long-lived cells that can harbor it for years. ART keeps the virus from actively replicating, but if you stop taking it, the virus re-emerges from these reservoirs. That’s why ART is a lifelong treatment.
Immune Recovery Over Time
With HIV held in check, your immune system begins to rebuild. CD4 cells, the white blood cells HIV destroys, gradually rise in number. Most people who achieve and maintain viral suppression see meaningful increases in their CD4 counts over the first one to two years. Clinicians generally look for a gain of at least 200 cells per cubic millimeter above baseline within 24 months as a sign that the immune system is responding well.
How much your immune system recovers depends heavily on where you started. People who begin ART early, before their CD4 count drops too low, tend to recover more fully. Those who start with CD4 counts of 500 or higher can reach near-normal immune function. People who begin treatment much later, after significant immune damage, may never fully restore their CD4 levels, even with years of successful viral suppression. This is one of the strongest arguments for starting treatment immediately after diagnosis.
Preventing Transmission
One of the most significant findings in HIV medicine is captured by the phrase U=U: undetectable equals untransmittable. According to the CDC, a person living with HIV who maintains an undetectable viral load on ART has zero risk of transmitting the virus to sexual partners. Not a low risk. Zero.
This conclusion comes from large studies that followed thousands of couples where one partner was HIV-positive and on treatment. Among those who maintained undetectable viral loads, there were no cases of sexual transmission. This applies to sex without condoms and regardless of the type of sexual activity. For many people living with HIV, this knowledge is as transformative as the health benefits of the medication itself.
Impact on Life Expectancy
Before effective treatment existed, an HIV diagnosis was often fatal within a decade. ART has fundamentally changed that. Between 2014 and 2016, a 21-year-old with HIV on treatment could expect to live to about 77, compared to about 86 for someone without HIV. That’s a gap of roughly 9 years, down from what was once a difference of several decades. For people who start treatment early, with CD4 counts still at 500 or above, the gap narrows further, with life expectancy reaching about 78 compared to 85 for uninfected adults in the same analysis.
The remaining gap is partly due to higher rates of certain chronic conditions in people with HIV, including heart disease and some cancers, and partly related to the long-term effects of the medications themselves. But the overall trajectory is clear: with consistent treatment, HIV has shifted from a fatal disease to a manageable chronic condition.
Long-Term Side Effects
ART is far more tolerable than earlier generations of HIV drugs, but it isn’t free of side effects over years of use. The most well-documented long-term concerns involve bone health, kidney function, and metabolic changes.
Bone loss is an early and relatively common effect. Studies show that bone mineral density can drop by about 6% in the first two years of treatment, regardless of which drug combination is used. Over time, this translates to higher rates of thinning bones and a greater risk of fractures, particularly for people on regimens that include certain older medications. The overlap between this drug-related bone loss and the natural bone loss that comes with aging makes this a growing concern as the HIV-positive population gets older.
Kidney problems are another consideration. Some ART drugs can damage the part of the kidney responsible for reabsorbing important minerals like phosphate. When this happens, phosphate leaks into the urine, which can weaken bones further and cause muscle weakness. Routine blood and urine monitoring helps catch this early, and switching to a different drug in the regimen typically resolves the problem.
Metabolic effects, including changes in cholesterol levels and blood sugar, are also seen with some regimens. These are managed much like they would be in anyone else: through monitoring, lifestyle adjustments, and sometimes additional medications.
Why Consistency Matters
ART only works if you take it consistently. When doses are missed, the drug levels in your blood drop low enough for HIV to start replicating again. Each time the virus copies itself, there’s a chance it will mutate. Some of those mutations can make the virus resistant to one or more of the drugs in your regimen, meaning those medications will no longer work even when you take them correctly.
Drug resistance can force a switch to alternative medications that may be less convenient, have more side effects, or be less effective. In rare cases, the virus can develop resistance to multiple drug classes, severely limiting treatment options. Modern regimens are more forgiving of the occasional missed dose than older ones were, but the principle holds: the more consistently you take ART, the better it works and the longer it keeps working.
For people who struggle with daily pills, long-acting injectable forms of ART are now available. These are given as infrequent injections, reducing the burden of daily adherence while maintaining viral suppression.